Valuation: ConvaTec Group

Market Cap 6.02B 5.16B 4.83B 4.42B 8.29B 576B 8.4B 57.01B 22.23B 289B 22.61B 22.11B 957B P/E 2026 *
24.2x
P/E 2027 * 16.9x
Enterprise Value 7.37B 6.31B 5.9B 5.4B 10.14B 705B 10.28B 69.76B 27.2B 354B 27.66B 27.06B 1,171B EV / Sales 2026 *
2.88x
EV / Sales 2027 * 2.62x
Free-Float
95.17%
Yield 2026 *
2.57%
Yield 2027 * 2.92%
Manager TitleAgeSince
Chief Executive Officer 62 04/08/2025
Director of Finance/CFO 51 04/08/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 71 14/08/2017
Chairman 78 30/09/2019
Director/Board Member 62 02/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.02B
+2.19%+4.84%-11.64%+12.29% 198B
+1.14%+2.28%+2.47%+14.39% 118B
+1.06%+1.34%+4.88%+75.73% 60.05B
-1.37%-6.57%+28.86%+58.31% 53.18B
+2.33%+4.69%-2.35%-30.34% 51.11B
+2.35%+2.89%+14.54%-11.79% 34.05B
+5.16%-4.14% - - 28.58B
-0.20%+1.05%+45.52%-10.08% 24.9B
-0.29%-3.87%-6.22%+24.74% 23.94B
Average +1.24%+0.70%+9.51%+16.66% 65.72B
Weighted average by Cap. +1.49%+2.11%+2.10%+18.06%

Financials

2026 *2027 *
Net sales 2.56B 2.19B 2.05B 1.88B 3.52B 245B 3.57B 24.21B 9.44B 123B 9.6B 9.39B 406B 2.73B 2.34B 2.19B 2B 3.76B 261B 3.81B 25.87B 10.09B 131B 10.26B 10.03B 434B
Net income 248M 213M 199M 182M 342M 23.75B 346M 2.35B 917M 11.93B 932M 912M 39.47B 360M 308M 289M 264M 496M 34.45B 502M 3.41B 1.33B 17.3B 1.35B 1.32B 57.24B
Net Debt 1.35B 1.15B 1.08B 987M 1.85B 129B 1.88B 12.75B 4.97B 64.69B 5.05B 4.94B 214B 1.15B 983M 920M 842M 1.58B 110B 1.6B 10.86B 4.24B 55.15B 4.31B 4.21B 182B
Logo ConvaTec Group
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA